Five Prime Therapeutics Inc
Combination Anti-CSF1R and Anti-PD-1 Antibody Combination Therapy for Pancreatic Cancer

Abstract:

The present invention relates to methods of treating pancreatic cancer with particular dosage regimes of antibodies that bind colony stimulating factor 1 receptor (CSF1R) (e.g. cabiralizumab) in combination with antibodies that bind programmed cell death 1 (PD-1) (e.g. nivolumab).